Research has shown that SLC27A2 induces cisplatin resistance in lung cancer stem cells through negative regulation of downstream signaling pathways, and the decrease in SLC27A2 is associated with chemotherapy response and poor patient survival [26]. This evidence concerns the gene SLC27A2 and lung carcinoma.